Breast Cancer-targets And Therapy BREAST CANCER-TARGET ISSN:1179-1314 E-ISSN:1179-1314 投稿咨询学术服务 基本信息 BASIC INFORMATION 审稿时间:16 Weeks 出版周期:1 issue/year 出版国家或地区:United Kingdom 创刊:暂无数据 影响因子:3.3 是否预警:否...
Current Drug Targets - ImmuneEstlin EJ. Novel targets for therapy in paediatric oncology. Curr Drug Targets Immune Endocr Metabol Disord. 2002;2:141-150.Estlin EJ. Novel targets for therapy in paediatric oncology. Current Drug Targets-Immune, Endocrine & Metabol Disorders. 2002; 2:141-150....
While tumour cell death can result in response to therapy, the selection, growth and dissemination of resistant cells can ultimately be fatal. In this Review, we present the main apoptosis pathways and other signalling pathways that interact with them, and discuss actionable molecular targets, ...
X., ... & Verset, G. (2023). Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. The Lancet.
TAMs express molecular triggers of checkpoint proteins that regulate T-cell activation, and are targets of certain checkpoint-blockade immunotherapies. Other macrophage-centred approaches to anticancer therapy are under investigation, and include: inhibition of macrophage recruitment to, and/or survival in...
7‑Difluoromethoxyl‑5,4'‑di‑n‑octylygenistein targets the STAT3 pathway by upregulating microRNA‑152‑3p expression to inhibit self‑renewal and tumor growth in non‑small cell lung carcinoma Qing Yuan, Xiang Li, Xuemei Chen, Jianhui Xiao, Jiansong Zhang ...
and phospho-proteome analysis. We discovered that genetic heterogeneity dictates functional heterogeneity across molecular layers and demonstrates that NF1 mutation drives mesenchymal signature. Most importantly, we found that glycerol ...
SCG101 Shows Antiviral and Antitumor Activity in Advanced HBV-Related HCC ByAshling Wahner May 8th 2025 SCG101 T-cell therapy was safe and induced sustained HBV clearance and antitumor activity in patients with advanced HBV-related hepatocellular carcinoma. ...
who progressed during or after first-line fluoropyrimidine plus platinum therapy with or without HER-2-targeted therapy with OS as the primary endpoint; 228 patients were randomized to weekly T-DM1 and 117 to taxane. 77.4% had previously received HER-2-targeted therapy, and 46.1% were Asian. ...
et al. Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy. Mod. Pathol. 27, 271–280 (2014). CAS PubMed Google Scholar Kawamata, F. et al. Copy number profiles of paired primary and metastatic colorectal cancers. Oncotarget 9, ...